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Abstract 
Aims
Amyloid β oligomers (AβO) are potent modulators of Alzheimer’s pathology, yet their 
impact on one of the earliest brain regions to exhibit signs of the condition, the locus 
coeruleus (LC), remains to be determined. Of particular importance is whether AβO 
impact the spontaneous excitability of LC neurons. This parameter determines brain-wide 
noradrenaline (NA) release, and thus NA-mediated brain functions, including cognition, 
emotion and immune function, which are all compromised in Alzheimer’s. Therefore, the 
aim of the study was to determine the expression profile of AβO in the LC of Alzheimer’s 
patients and to probe their potential impact on the molecular and functional correlates of 
LC excitability, using a mouse model of increased Aβ production (APP-PSEN1).
Methods and Results
Immunohistochemistry and confocal microscopy, using AβO-specific antibodies,  
confirmed LC AβO expression both intraneuronally and extracellularly in both Alzheimer’s 
and APP-PSEN1 samples. Patch clamp electrophysiology recordings revealed that APP-
PSEN1 LC neuronal hyperexcitability accompanied this AβO expression profile, arising 
from a diminished inhibitory effect of GABA, due to impaired expression and function of 
the GABA-A receptor (GABAAR) α3 subunit. This altered LC α3-GABAAR expression 
profile overlapped with AβO expression in samples from both APP-PSEN1 mice and 
Alzheimer’s patients. Finally, strychnine-sensitive glycine receptors (GlyRs) remained 
resilient to Aβ-induced changes and their activation reversed LC hyperexcitability. 
Conclusions
The data suggest a close association between AβO and α3-GABAARs in the LC of 
Alzheimer’s patients, and their potential to dysregulate LC activity, thereby contributing to 
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Introduction
Synaptic dysfunction is a key pathological mechanism underlying the mild cognitive, 
memory and neuropsychiatric impairments that typify the earliest stages of Alzheimer’s 
[1-3]. Given the brain’s established propensity for synaptic remodelling, identifying the 
molecular and cellular mechanisms of such synaptic pathology, prior to the onset of 
irreversible neuronal death, likely represents one of the best interventional strategies 
against this disease [4, 5]. Convergent lines of evidence point to a crucial role for the 
soluble, oligomeric variants of amyloid β (AβO) [6, 7] in mediating such synaptic 
dysregulation [8, 9]. 
Experimentally, AβO bind directly to synaptic junctions [9-11], alters excitatory and 
inhibitory synaptic transmission [12-14], the expression and location of synaptic 
neurotransmitter receptors [15, 16] as well influencing synaptic plasticity [14] and learning 
and memory [17]. This association is also evident in humans, with a strong association 
demonstrated between AβO and dementia [18, 19]. While such compelling evidence exist 
for AβO pathology in cortical brain regions, less is known about the impact of this 
pathway in one of the first regions to exhibit quintessential Alzheimer’s histopathology, 
namely the locus coeruleus (LC) [20, 21]. In particular, we do not know whether AβO-
related pathology alters the core determinant of LC-mediated brain functions, the 
spontaneous neuronal firing rate, and if so, through which mechanisms?
The relevance of LC neurobiology to the understanding of the spectrum Alzheimer’s-
related symptoms is underscored by the overlap between the brain functions, this system 
modulates, and those that are impaired in this condition. These include cognition [22], 
arousal [23], emotion [24] and the stress response [25]. The coordinated brain-wide 
release of the LC’s signature neurotransmitter noradrenaline (NA), and thus LC-NA 
mediated brain functions, arises from the complex firing patterns of LC neurons, which 
are brain [26], behaviour [23, 27] and disease-state [28] dependent. This emphasises the 
importance of understanding the molecular machinery of the LC and how this contributes 
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The focus on Alzheimer’s pathology within the LC has been predominantly on 
hyperphosphorylated tau tangles [21] because of their early presence during the disease 
spectrum. Despite confirmation of the native expression of LC intraneuronal Aβ peptides 
in rodents at least [30, 31], Aβ-related pathology has largely been overlooked because 
only insoluble Aβ-containing plaques have been documented within the LC, and they are 
present only in the final stages of the condition [32]. Therefore, neither the presence of 
the more toxic soluble AβO within LC, nor their effects on LC neuronal excitability, have 
been demonstrated. This is important because of the evidence indicating that AβO, rather 
than Aβ plaques, mediate the neuro-toxic effects of the Aβ pathway [33, 34]. Of particular 
relevance to the LC, and its early involvement in Alzheimer’s pathology, is the emerging 
synergistic role of AβO in tau tangle formation [35, 36]. Intriguingly, while notable LC 
neuronal loss, attributed to tauopathy, is a core feature in Alzheimer’s [37], there appears 
to be discordance between the onset of such pathology, and LC neurodegeneration [20]. 
Given such considerable evidence, it is reasonable to speculate that in the LC, initial, pre-
symptomatic insults in the form of tau tangle and AβO interactions, cooperate to set in 
motion a range of pathological changes such as synaptic dysfunction, oxidative stress 
[38] and altered LC excitability [28]. Such changes are likely to prove crucial in terms of 
the long-term viability of cells not only within the LC, but also in other brain regions 
because impaired LC integrity directly influences the progression of Alzheimer’s 
pathology in cortical regions [39, 40]. To begin to explore the potential influence of AβO 
on the LC-NA system, and thus connected brain regions, we investigated the impact of 
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Materials and Methods
See the Supplementary Information (SI) section for detailed descriptions of methodology.
Animals
The B6C3-Tg (APPswe, PSEN1dE9) double transgenic mouse model, that results in 
accelerated production of Aβ [41], (APP-PSEN1), bred on a C57BL/6J background strain, 
2 and 4 months of age, was the main strain used in the study. In all experiments, wild 
type (WT) littermates were used as controls for APP-PSEN1 subjects. In a subset of 
experiments, GABAAR α3 subunit gene deleted (α3–/–) mice and their WT littermates [42], 
bred on a C57BL/6J background, as well as mice expressing green fluorescent protein 
(GFP) under the promotors of the astroglial cytoskeletal protein, glial fibrillary acidic 
protein (GFP‐GFAP) [43] were used. Male mice were used throughout all experiments.
Human tissue
Formalin-fixed, paraffin embedded, 8 µm thickness brain sections containing the LC were 
provided by Brains for Dementia Research tissue banks, from n = 5 control and 5 
Alzheimer’s subjects. Demographic details of the subjects are detailed in SI Table 1.
Immunohistochemistry and confocal microscopy
Experiments were conducted according to previously described protocols [44]. Briefly, 
mice were transcardially perfusion fixed with 1% paraformaldehyde. The brains were 
sectioned using a vibratome and tissue sections incubated using a range of primary and 
secondary antibodies (see SI Table 2 for details of primary antibodies used). Sections 
were examined with a confocal laser-scanning microscope (LSM710 or LSM880; Zeiss, 
Germany), images were processed using Zen 2009 Light Edition (Zeiss) and figures 
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Whole-cell patch clamp electrophysiology LC recordings in acute brain slices of AP-
PSEN1 and WT 
Spontaneous LC firing rate (FR), in the absence or presence of a range of 
neurotransmitter modulators, was determined in 2-4 month-old mice, according to 
previously published protocols [45, 46]. 
Quantitative reverse transcription polymerase chain reaction (qPCR)
Changes in the mRNA levels for the following inflammatory genes were quantified in 
samples from the LC and hippocampus, according to our previously published protocols 
[47]: IL1β, IL6, CSF1, CLC2/3; IBA1, TNFα (see SI for primer details). 
Enzyme-linked immunosorbent assay (ELISA)
An ELISA was used to measure the concentration of NA (catalogue number BA E-5200, 
LDN, Germany) in blood and brain respectively, according to manufacturer’s protocols
Statistical analysis
The individual statistical tests used to assess specific data sets are indicated in the 
Results section. An alpha-level of less than 0.05 that was used to determine statistical 
significance. For graphical presentation of quantitative data, symbols represent individual 
data points, bars represent the means and the error bars the SEM. In all cases, 
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Results
Expression of AβO within the LC of Alzheimer’s patients and APP-PSEN1 mice 
While plaques composed of fibrillar Aβ have been reported in the LC of Alzheimer’s 
patients, localisation of oligomers in this brain region remain to be demonstrated. 
Immunoreactivity for an antibody (4G8), which recognises both fibrillar and oligomeric 
forms of Aβ, presented predominantly as extracellular plaques within the LC of post-
mortem samples from Alzheimer patients. There was minimal apparent association with 
noradrenergic profiles (Fig. 1 A1). This is in agreement with previously published reports 
[32]. No specific signal was detected in human control samples (SI Fig. 1 A). In 
comparison to Alzheimer’s samples, Aβ immunoreactivity in the LC of APP-PSEN1 mice, 
using antibodies that recognise different sequences of the peptide (clones 4G8 and WO-
2), invariably presented as cytoplasmic signal within TH-immunopositive neurons as well 
as TH-immunonegative cells [44] (Fig. 1 A2-4). This expression pattern is similar to 
previous reports of native LC Aβ expression in rodent [30, 31]. No specific signal was 
detected in WT samples (SI Fig. 1 B). The LC TH-immunonegative, Aβ-immunopositive 
cells were confirmed to be neurons, using the pan-neuronal marker HuC [48], (SI Fig. 
2A). They were further distinguished by the expression of calretinin (SI Fig. 2B) or 
calbindin (SI Fig. 2C).
Even though native LC Aβ expression has been demonstrated in rodent in a manner 
similar to the cytoplasmic profile in Fig. 1 A2-4, an important caveat for the above data is 
that the 4G8 and WO-2 antibodies used in this study are capable of binding to APP in 
addition to Aβ. We therefore confirmed the expression of AβO, in LC neurons, using 
AβO-specific antibodies. Two different antibodies were used that have been 
demonstrated to specifically recognise human AβO in samples from Alzheimer’s patients, 
and not control human subjects, here termed NU1 and NU2 [49]. Both antisera have 
been shown to exhibit strong binding to trimers, tetramers, and 12–24mer, but not 
monomers [49]. AβO-NU2, produced intense cytoplasmic staining of LC neurons in 
Alzheimer’s samples, as well as numerous extracellular immunoreactive clusters (Fig. 1 
B). No specific signal was detected in human control samples (SI Fig. 3 A), in agreement 
with previous evidence using cortical samples [49]. This suggests a novel significant 
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overview of immunoreactivity for AβO-NU2 in the LC of APP-PSEN1 mice revealed a 
largely intraneuronal pattern that closely mirrored that found in Alzheimer’s samples (Fig. 
1 C1-2). Whilst the signal was distributed widely throughout the LC, it was noticeable that 
some TH-immunopositive cells were devoid of any AβO-NU2 immunoreactivity (Fig. 1 
C3). Higher resolution inspection indicated that AβO-NU2 immunoreactivity was 
concentrated in TH-immunopositive somata, dendrites and fine processes suggestive of 
axons, and extracellular clusters (Fig. 1 C4). We used WT mouse samples to confirm the 
specificity of APP-PSEN1 AβO-NU2 signal since they lack human APP or Aβ (SI Fig. 
3C). Immunoreactivity for AβO-NU1 in APP-PSEN1 mice closely resembled that of AβO-
NU2. However, a notable difference was the significant variation in the intensity of signal 
between different LC TH-immunopositive neurons (Fig. 1 D), suggesting different 
expression levels across LC noradrenergic neurons. No specific AβO-NU1 signal was 
detected in WT mouse samples (SI Fig. 3B). Despite strong AβO-NU1 immunoreactivity 
being previously reported using human cortical samples [49], we were unable to detect 
any specific AβO-NU1 signal in the LC of patient samples (data not shown). 
A proposed pathway for intraneuronal AβO in Alzheimer’s pathogenesis is its 
incorporation into the mitochondrial matrix and disruption of cellular bioenergetics [50]. 
Immunoreactivity for citrate synthase, an enzyme located within the mitochondrial matrix 
[51], was used to explore the association between AβO-NU1/2 and mitochondrial 
compartments in APP-PSEN1 mice. There was a significant overlap between somatic 
immunoreactivity for AβO-NU1 (Fig. 1 E1-2) and AβO-NU2 (Fig. 1 F1-2) and the signal 
for citrate synthase. Quantification of the degree of colocalised pixels between citrate 
synthase:AβO-NU1 (Fig. 1 E3) and citrate synthase:AβO-NU2 (Fig. 1 F3) revealed 
positive correlations for both the degrees of co-occurrence of overlapping pixels, using 
the Manders’ overlap coefficient [52], (NU1: median, range; 0.5, 0.1 - 0.9, n = 100 cells, 
Fig. 1 E3), (NU2: median, range:  0.6, 0.33-0.9, n = 100 cells, Fig. 1 F3) as well as the 
intensities of overlapping pixels, using the Pearson’s correlation coefficient [53] (NU1: 
median, range; 0.4, 0.1 - 0.7, n = 100 cells, Fig. 1 E3), (NU2: median, range: 0.4, 0.2-0.8, 
n = 100 cells, Fig. 1 F3). There was also a striking overlap of citrate synthase-AβO-NU1/2 
for immunoreactive clusters neighbouring the periphery of somata and dendrites, which 
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A consequence of AβO-mediated mitochondrial dysfunction is oxidative stress [38, 54] 
with mitochondrial oxidative stress associated with the FR and viability of LC neurons 
[28]. A key mitochondrial enzyme in this process is superoxide dismutase 2 (SOD2). It 
provides protection against AβO-mediated oxidative stress [55] and its expression is 
decreased in Alzheimer’s [56]. We detected a positive association for the location of 
SOD2 immunoreactive clusters with both AβO-NU1 (Fig. 1 G) and AβO-NU2 (Fig. 1 H). In 
comparison to WT samples, there was a noticeable decrease in the intensity of SOD2 
immunoreactivity in the LC of APP-PSEN1 mice (Fig. 1 I1-6), which was borne out by a 
quantitative assessment of the respective fluorescence intensities, in samples reacted 
and imaged under identical conditions (P = 0.02, two-tailed unpaired Student’s t test; n = 
5 animals) (Fig. 1 I7). This collectively suggests a strong association of intraneuronal 
AβO with mitochondrial compartments of LC neurons.
Neuroinflammation is a core component of Alzheimer’s pathology with both Aβ fibrils [57] 
and AβO mediating specific pathways [58]. A distinctive feature of Alzheimer’s related 
neuroinflammation is the presence of activated microglia. We therefore assessed the LC 
of APP-PSEN1 mice for signs of altered immune status, using the microglia/macrophage-
specific calcium-binding protein ionized calcium binding adaptor molecule 1 (IBA1), the 
expression of which is increased in Alzheimer’s-associated neuroinflammation [57]. TH-
immunopositive neurons in the LC of APP-PSEN1 mice appeared to be contacted by a 
greater number of IBA1-immunoreactive profiles which were also more ramified, 
compared to WT, suggesting increased expression levels of this inflammatory marker 
(Fig. 1 J1-2). This increased expression was confirmed at both mRNA (P = 0.0053, two-
tailed unpaired Student’s t test; n = 10 animals) (Fig. 1 J3) and cell density levels (P 
<0.0001, two-tailed unpaired Student’s t test; n = 10 animals) (Fig. 1 J4). The production 
of inflammatory cytokines is considered to be a consequence of microglial activation in 
Alzheimer’s [57]. Since the LC of APP-PSEN1 mice exhibits only the oligomeric forms of 
Aβ, whilst oligomeric as well as fibrillar expression is evident in cortical regions, we 
assessed whether there were differences in the levels of inflammatory cytokines between 
the LC and hippocampus. Accordingly, we detected contrasting cytokine expression 
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receptor (CSF1), which is anti-inflammatory and prevents the progression of Alzheimer’s-
like pathology [59], was significantly decreased in the LC (P = 0.0013, 2-ANOVA, Sidak’s; 
n = 5 animals), yet upregulated in the hippocampus (P = 0.0045, 2-ANOVA, Sidak’s; n = 
5 animals) (Fig. 1 J5). Since CSF1 signalling purportedly promotes neuroprotection [60], 
its contrasting expression profiles in the LC and hippocampus, as a result of Alzheimer’s-
like pathology, could be a contributing factor to the early vulnerability of the LC to 
Alzheimer’s. In contrast, whilst the mRNA levels for interleukin 1 beta (IL-1β) (P= 0.0081, 
two-way ANOVA with Sidak’s; n = 5 animals) (Fig. 1 J6) and chemokine (C-C motif) 
ligand 3 (CCL3) (P = 0.0216, 2-ANOVA, Sidak’s; n = 5 animals) (Fig. 1 J7) were 
significantly increased in hippocampal samples, no significant changes were detected in 
the LC. 
AβO are associated with LC synapses and LC neuronal hyperexcitability in APP-PSEN1 
mice 
Apart from the cytoplasmic expression profile of AβO-NU1-2 outlined above, numerous 
extracellular immunoreactive clusters that decorated LC neuronal surfaces were also 
evident. Since AβO have been shown to interact at synaptic domains [49], we next 
assessed the association of AβO immunoreactivity with signal for synaptic marker 
proteins. In APP-PSEN1 mice, clusters immunoreactive for AβO-NU2 were located in 
close apposition to puncta immunopositive for the synaptic vesicle glycoprotein 2A 
(SV2A) (Fig. 2 A). This protein is expressed in excitatory and inhibitory synapses and is 
thus representative of the location of all synaptic junctions [61]. Furthermore, AβO-NU2 
immunoreactivity was in close contact with clusters immunoreactive for the vesicular 
GABA transporter (VGAT), a marker of inhibitory synapses (Fig. 2 B) as well as the 
vesicular glutamate 2 (VGLUT2), a marker of excitatory synapses (Fig. 2 C). 
Given the important role that synaptic transmission has in setting the spontaneous firing 
rate (FR) of LC neurons, and the established impact of AβO on synaptic transmission 
discussed previously, we next assessed the functional consequences of the increased 
AβO expression in APP-PSEN1 mice, by recording LC spontaneous FRs from identified 
NA LC neurons (Fig. 2 D). APP-PSEN1 LC neurons exhibited significantly greater FRs (P 
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D2-3) and decreased membrane time constant compared to WT (P = 0.038, two-tailed 
unpaired Student’s t test, n = 9 cells) (Fig. 2 D4). No other changes in LC physiological 
parameters were detected (Table 1). Accompanying this enhanced LC excitability was a 
significant decrease in NA concentration in the LC (P = 0.0032, 2-ANOVA, n =5 animal), 
and a significant increase in the hippocampal content (P < 0.0001, 2-ANOVA, n =5 
animal) (Fig. 2 E). 
In light of this heightened excitability of LC neurons, we next assessed whether this could 
be due to changes in inhibitory modulation. GABA and glycine provide the predominant 
inhibitory modulation of LC neurons [62]. We therefore explored whether the increased 
levels of AβO in AP-PSEN1 impacts on these pathways in regulating basal spontaneous 
FR. Using a recording electrode solution that is representative of the native intracellular 
Cl- ion concentration, bath-applied GABA induced a concentration dependent decrease in 
the spontaneous FR of WT LC neurons with an approximate IC50 of 100 nM (Fig. 2 F1). 
With this concentration of GABA, there was a significant drug [F (1, 18) = 12.38, P = 
0.0025, two-way ANOVA with repeated measures (2-RMA)] and genotype [ F (1, 18) = 
7.685, P = 0.0126, 2-RMA] effect on FR. However, post-hoc analysis revealed that while 
GABA (100 nM) significantly inhibited FR in WT cells (P = 0.0142, Sidak’s; n = 7 cells), 
this effect was abolished in cells from APP-PSEN1 mice (P = 0.1665, Sidak’s; n = 12 
cells) (Fig. 2 F2). Calculating the percentage of inhibition induced by this concentration of 
GABA revealed a significant decrease in response of APP-PSEN1 neurons (P = 0.0201, 
unpaired Student’s t test) (Fig. 2 F3). This impaired GABAergic receptor response could 
be due to changes in either GABAA or GABAB receptor (GABAA-BR) subtypes. However, 
a previous electrophysiological report demonstrated that the predominant effect of GABA 
on LC neurons was mediated via GABAARs, with only significantly higher concentrations 
(> 600 µM) activating GABABRs [63]. We verified this predominant association of GABA 
with GABAARs at the molecular level with immunoreactive clusters for the vesicular 
GABA transporter (VGAT), a marker of GABA and glycine release sites, being 
immediately adjacent to cluster immunoreactive for gephyrin, a protein that anchors 
GABAAR and GlyRs in postsynaptic junctions (Fig. 2 G1). In contrast, sparse 
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associated with VGAT immunoreactivity (Fig. 2 G2). We therefore focussed further on 
GABAARs and GlyRs. 
Impaired α3-GABAARs in LC neurons of Alzheimer’s patients and APP-PSEN1 mice
Complex changes in the native expression patterns of various GABAAR subunits have 
been reported in a range of cortical brain regions of Alzheimer’s patients [64]. While the 
complement of GABAAR subunits expressed within the mouse and human LC nucleus 
has been demonstrated [65], confirmation of the neurochemical identity of the LC cell 
types expressing specific subunits, at high resolution, remains to be reported. In 
agreement with a previous report in rat [44], the GABAAR α1 subunit was exclusively 
expressed in TH immunonegative cells of mouse (Fig. 3 A1-3) and human (Fig. 3 A4). In 
contrast, immunoreactivity for the α3 subunit in this region of the brainstem strictly 
overlapped with that of TH, both within the LC nuclear core and the pericoeruleur 
dendritic regions of the mouse LC (Fig. 3 B1-2), suggesting a significant contribution of 
this subunit to GABA-mediated regulation of the LC-NA system. The specificity of this 
labelling pattern was confirmed using tissue from α3 subunit gene deleted mice (α3-/-) in 
which no specific signal was detectable (Fig. 3 B3-4). 
High resolution inspection revealed that the majority of α3 subunit immunoreactive 
clusters were located on plasma membrane surfaces of TH immunopositive neurons 
immediately adjacent to GABA release sites, identified by immunoreactivity for VGAT in 
mouse (Fig. 3 C1-3). This pattern of α3 subunit immunoreactivity being concentrated on 
somatodendritic surfaces of LC NA neurons was replicated in control human samples 
(Fig. 3 C4). We were unable to detect any specific signal for the α2 subunit (or any other 
α subunit) in LC neurons, even though we were able to reproduce the quintessential 
immunoreactivity pattern for this subunit which others have demonstrated in other brain 
regions such as the hippocampus (SI Fig. 4). TH immunopositive neurons also displayed 
immunoreactivity for the γ2 (Fig. 3 D1) and β3 (Fig. 3 D2) subunits, with these subunits 
being closely associated with one another (Fig. 3 D3), Furthermore, the α3 (Fig. 3 E1) 
and β3 (Fig. 3 E2) subunits were also closely associated with one another (Fig. 3 E3), 
suggesting that α3-β3-γ2 are the subunit combinations forming the major GABAAR 
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The importance of α3-GABAARs in setting the spontaneous LC FR was confirmed in cells 
from α3-/- mice, which displayed a significantly higher basal FR compared to WT 
littermates (P = 0.0048, two-tailed unpaired Student’s t test; n = 21 WT cells and 16 α3-/- 
cells) (Fig. 3 E1). Additionally, the α1/2/3/5-GABAARs positive allosteric modulator TP003 
[66], which is likely to induce its effects on LC-NA neurons predominantly via α3-β/γ-
GABAARs due to the absence of other α subunits in this cell type, significantly inhibited 
the FR of neurons from WT mice (P = 0.0099, two-tailed paired Student’s t test; n = 5 
cells) (Fig. 3 E2). Presumably this effect of TP003 reflects an action of the drug to 
enhance the effects of ambient GABA on α3-GABAARs. Nevertheless, we cannot exclude 
an indirect action on adjacent α1 immunopositive, TH-immunonegative LC cells. 
Collectively, these data suggest that α3-GABAARs are integral in setting the basal level of 
LC neuronal activity, and therefore LC-mediated brain functions and behaviours.
Given the above-mentioned importance of α3-GABAARs to LC activity, we next explored 
their expression and function in APP-PSEN1 mice. Clusters immunoreactive for the α3 
subunit were noticeably fewer and smaller in APP-PSEN1 samples, with the majority of 
the signal located within the cytoplasm of TH immunopositive neurons, rather than the 
characteristic clustering on plasma membrane surfaces (Fig. 4 A, B). We detected 
significant decreases in α3 cluster density (P < 0.0001, two-tailed unpaired Student’s t 
test; n = 40 cells from 4 WT animals and n = 50 cells from 5 APP-PSEN1 animals), size 
(P < 0.0001; two-tailed unpaired Student’s t test), fluorescence intensity (P < 0.0001; two-
tailed unpaired Student’s t test) and percentage of the cell area they covered (P < 
0.0001; two-tailed unpaired Student’s t test) (Fig. 4 C). In APP-PSEN1 mice, there was a 
noticeable overlap between pools of α3 and AβO-NU2 immunopositive clusters, both 
within the cytoplasm of somata and dendrites (Fig. 4D). The functional consequences of 
this Aβ-altered α3 profile was confirmed by TP003 which significantly decreased the FR 
of WT cells (P = 0.04, 2-RMA, Sidak’s; n = 5 cells), yet had a negligible and non-
significant effect in APP-PSEN1 cells (P = 0.9894, 2-RMA, Sidak’s; n = 6 cells) (Fig. 4 E). 
We sought to confirm these potentially AβO-mediated changes in LC α3 subunit 
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Aβ expression in this brain region. The α3 subunit immunoreactivity pattern in such 
samples was indistinguishable to that obtained in APP-PSEN1 mice, being preferentially 
located in cytoplasmic compartments occupied by TH immunoreactivity (Fig. 4 F1-6). 
This preponderance of α3 expression in cytoplasmic rather than membrane domains in 
Alzheimer’s tissue was confirmed by quantifying the degree of colocalization between 
immunoreactivity for α3 and TH, since TH is expressed exclusively in cytoplasmic 
compartments. There was a significant difference in the distributions for the α3-TH 
Manders’ colocalization coefficients between control and Alzheimer’s samples (P 
<0.0001, Kolmogorov-Smirnov, n = 110 cells from 5 patients in each category) (Fig. 4 
F7). In such patients’ samples, there was no discernible interaction between 
immunoreactivity for α3 and Aβ immunopositive plaques (Fig. 4 G). In stark contrast, a 
significant association between α3 and AβO expression was evident with the 
considerable overlap between these signals throughout neuronal compartments (Fig. 4 
H). 
GlyRs and transporters are resistant to AβO pathology in APP-PSEN1 mice and their 
modulation reverses LC hyperexcitability
We next explored whether the inhibitory drive arising from the LC GlyR-GlyT systems is 
also influenced by the elevated levels of AβO in APP-PSEN1 mice, firstly by 
characterising these systems in the WT mouse. Immunoreactivity for GlyR subunits was 
located throughout somatodendritic surfaces of TH immunopositive neurons, in close 
proximity to VGAT immunopositive clusters (Fig. 5 A), and their pharmacological 
activation decreased LC FR (Fig. 5 B). Immunoreactivity for the glycine transporters one 
and two (GlyT1-2) [67] was concentrated on astrocytic and axonal profiles respectively 
(Fig. 5 C1-3, D1-3). In addition, inhibition of GlyT1, using ASP2535 [68] (1 µM) (P = 
0.0015, two-tailed paired Student’s t test; n = 8 cells) and GlyT2, using ALX1393 [69](1 
µM), (P = 0.0006; two-tailed paired Student’s t test; n = 11 cells) both significantly 
decreased LC FR (Fig. 5 C4, D4). Thus, the activity of both GlyRs and GlyT subtypes 
contributes to setting the basal LC FR.
In light of the above potential to pharmacologically exploit this coexisting inhibitory 
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systems in the APP-PSEN1 model. There were no differences between WT and APP-
PSEN1 mice in terms of the pattern (Fig. 6 A1-4), density (P = 0.5299, two-tailed 
unpaired Student’s t test; n = 8 animals) (Fig. 6 A5) and cluster size (P = 0.9250, two-
tailed unpaired Student’s t test; n = 8 animals) (Fig. 6 A6) of GlyR immunoreactive 
clusters. Importantly, glycine (30 nM) significantly reduced APP-PSEN1 LC neurons FRs 
[F (1, 17) = 24.05, P = 0.0001; 2-RMA] in LC FR for both WT (p = 0.0140, Sidak’s; n = 10) 
and APP-PSEN1 (P = 0.0026, Sidak’s; n = 9) cells (Fig. 6 A7). Although there was a 
decrease in GlyT2 immunoreactive cluster density (P = 0.0341, two-tailed unpaired 
Student’s t test; n = 7 animals) (Fig. 6 B1-5) and cluster size (P = 0.0244, two-tailed 
unpaired Student’s t test; n = 7 animals) (Fig. 6 B6), no such changes were detected for 
GlyT1 (data not shown). This was further confirmed, using the GlyT1 inhibitory ASP2535, 
which also reversed LC hyperexcitability in LC neurons [F (1, 14) = 54.77, P < 0.0001, 2-
RMA) of WT (P = 0.0006, Sidak’s; n = 10 cells) and APP-PSEN1 (P = 0.0001, Sidak’s; n 
= 10 cells) mice (Fig. 6 B7). This therefore identifies this pathway as a potential strategy 
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Discussion
The study reveals for the first time, the expression profile of AβO in the LC in Alzheimer’s 
patients, one which is replicated in the APP-PSEN1 mouse model of increased Aβ 
production. Consequences of this elevated production of Aβ included an array of 
molecular changes involving immune, neurochemical and metabolic pathways, 
accompanied by neuronal hyperexcitability and altered NA brain levels. The data provide 
unique insights into the impact of AβO pathology in a brain region first to exhibit 
quintessential Alzheimer’s pathology. 
Importance of AβO in the LC in Alzheimer’s
The LC features prominently in assessments of the earliest pathological stages of 
Alzheimer’s, with the predominant characteristic being the presentation of tau tangles in 
this locus, prior to other brain regions [20]. In stark contrast, the other post mortem 
pathological hallmark of Alzheimer’s, Aβ plaques, is largely overlooked as a contributor to 
the LC disease spectrum due to the relatively belated presentation of such pathology in 
this brain region, in most cases only at Braak stages V-VI [21]. However, the importance 
of the Aβ system in contributing to the initial stages of Alzheimer’s could be a significant 
oversight due to recent evidence indicating that intraneuronal AβO accumulation 
precedes tau pathology in the entorhinal cortex, which alongside the LC, presents earliest 
with Alzheimer’s pathology [70]. Furthermore, compelling data indicate that AβO, rather 
than Aβ plaques impart the predominant toxic burden for this pathway [33]. More 
importantly, especially in terms of the disease phenotype in the LC, converging evidence 
points to a synergistic role between tau and AβO in mediating Alzheimer’s pathology [3, 
71, 72]. Indeed, AβO have been shown to enhance, whereas Aβ fibrils reduce, the 
aggregation of tau [35]. Furthermore, AβO promote the uptake of tau fibril seeds 
potentiating intracellular aggregation [73] and mediate neurite degeneration [74]. 
Mechanistic insights into this AβO-tau interaction arise from intriguing new data that 
demonstrate the involvement of NA, and α2A adrenergic receptors (α2AARs) in mediating 
tau hyperphosphorylation and Alzheimer’s-related pathology in human and animal 
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feedback modulation of LC neuronal activity via α2AARs [76] [77], dysregulation of LC 
hyperexcitability, in combination with locally produced AβO, could set in motion the early 
levels of tau tangle formation distinctive in this brain region. Therefore, a systematic 
analysis of the relative temporal expression profiles for the presentation of tau tangle and 
AβO, rather than Aβ plaques on their own, could provide a more insightful view into the 
early stages of Alzheimer’ disease. 
Despite the recognised importance of the LC in Alzheimer’s, relatively little is known 
about the functional changes which occur in the constituent neurons of this nucleus. 
Whilst various brain imaging techniques have been used to examine the LC in patients at 
various stages of Alzheimer’s, most of these data relate to structural rather than 
functional changes [78, 79]. The current study provides, to the best of our knowledge, the 
first analysis of the effects of Aβ-related pathology on the key functional determinant of 
LC-NA activity, namely spontaneous FR, demonstrating increased activity at the single 
cell level. This increased FR is likely to negatively impact on a range of behaviours, 
including cognitive performance [26], a heightened stress response [80] an increase in 
anxiety-like behaviour [27] and increased wakefulness [23]. This in turn could help to 
elucidate the neurobiological basis for some of the key behavioural disturbances 
presented by early-stage Alzheimer’s patients, such as enhanced irritability, aggression 
and disturbances in sleep-wake cycles. Furthermore, if the increased LC FR evident in 
APP-PSEN1 mice proves to be a consistent feature in the early, pre-cognitive impairment 
stages of humans with the condition, this could inform recent priorities [29] to develop 
non-invasive early diagnostic strategies [81, 82]. 
AβO and the LC inhibitory neurotransmitter systems
A striking finding was the significant impairment in the inhibitory effect of GABA on the 
tonic FR and the altered expression and function of α3-GABAARs of LC neurons in APP-
PSEN1 mice. In light of the association of AβO-NU2 immunoreactivity with VGLUT2 
signal, we assessed whether there were any changes in glutamatergic synaptic markers 
in APP-PSEN1 mice. In both APP-PSEN1 mice and Alzheimer’s patients, there was a 
strong overlap between α3-GABAARs and AβOs but no association with extracellular 
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of presynaptic (VGLUT2) or postsynaptic (PSD-95) glutamatergic synaptic markers in 
APP-PSEN1 compared to WT mice (data not shown), suggesting a predominant impact 
of AβO on inhibitory synapse. Given this increased cytoplasmic and decreased 
membrane quotient for α3-GABAARs, the question therefore arises whether the increased 
interaction between α3-GABAARs and AβOs impairs its trafficking to the membrane or 
enhances its internalisation from such domains. There is evidence for both mechanisms. 
The APP-PSEN1 model results in increased expression of amyloid precursor protein 
(APP) and production of Aβ [83], both of which could impact on the cytoplasmic trafficking 
and internalisation processes. Firstly, there is a strong interaction between AβO and 
GABA or GABAARs. The application of GABA down-regulates the endocytosis of AβO, 
thereby decreasing intracellular levels and AβO-induced cytotoxicity in WT mice [84]. 
Furthermore, there is a bi-directional interaction between AβO and GABAARs. AβO 
impair GABAAR-mediated inhibition [85] by internalising GABAARs [16]. In contrast, 
chronic activation of GABAARs decreases Aβ25-35-mediated cytotoxicity [86]. 
An alternative explanation for the decreased α3 membrane expression could be an 
impairment in the trafficking of newly synthesised subunits to the membrane. GABAARs 
are assembled within the endoplasmic reticulum and transported to the Golgi apparatus 
for packaging onto vesicles [87]. Subsequently, they are transported to the plasma 
membrane, from where they diffuse laterally into synapses [88-90]. Several proteins are 
involved in transporting the GABAARs from the Golgi, within transport vesicles, to the 
plasma membrane and their subsequent phosphorylation. One of these proteins, PLIC-1, 
facilitates the entry of GABAAR into the secretory pathway [91]. Importantly, PLIC-1 
genetically associates with AD [92] and regulates APP, as well as Aβ trafficking and 
processing [93]. Furthermore, the amount of PLIC-1 directly determines its influence on 
GABAAR trafficking since its overexpression promotes GABAAR membrane insertion [91]. 
Since the APP-PSEN1 mouse model is based on increased expression of APP, most 
probably beyond physiological levels, the expected increased demand for APP and Aβ 
handling by PLIC-1 in such mice could result in APP processing pathways predominating 
to the detriment of other systems, including GABAARs, resulting in a compromised 
delivery to plasma membranes. A robust counter-argument to this is that post-mortem 
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expression profile to that observed in APP-PSEN1 samples. Indeed, in both mouse and 
human samples, a significant component of α3 immunoreactivity was located within 
cytoplasmic compartments, rather than the conventional enrichment on plasma 
membranes, suggesting that such altered trafficking of these receptors are a 
phenomenon of the disease itself, rather than the animal model; Finally, a more 
straightforward explanation could be AβO-mediated damage to the plasma membrane 
[94], which simply imposes space constraints for receptor insertion. 
This strong association between Alzheimer’s-related pathology and α3-GABAARs is 
unsurprising. The α3 subunit links a number of brain regions which are known to be 
adversely affected especially in the early stages of the condition. These include 
monoaminergic brainstem centres [44, 95, 96] which degenerate with loss of their cortical 
modulatory presence, fear or stress circuitry such as the amygdala [97] and bed nucleus 
of the stria terminalis [98], which most likely contribute to the neuropsychiatric symptoms, 
the olfactory system [98] and the established impairment of olfaction [99], and the 
entorhinal cortex [100] and its role during the stage of mild cognitive impairment. A likely 
reason for the vulnerability of these α3-GABAAR centres could be the limited repertoire of 
GABAAR subtypes expressed by their constituent neurons. For example, compared to 
cortical pyramidal neurons, which express multiple α subunits and are able to 
compensate for the loss of individual subunits with limited consequences on neuronal 
excitability [101], any impairment in α3-GABAAR function is likely to have a tangible effect 
on the inhibitory modulation of these brain regions. Since many of these neurons already 
expend a heavy metabolic load in terms of their spontaneous activity and brain wide 
projections using unmyelinated axons, any impairment in their inhibitory regulation and 
consequent hyperexcitability is likely to hasten their demise, thereby accounting for their 
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Table 1
Summary of basic membrane characteristics of recorded noradrenergic LC neurons in 
WT and APP-PSEN1 mice. Data are presented as the mean ± SEM, n = number of cells 
used per parameter.
Parameter





Spontaneous FR, Hz 
(n)
2.57 ± 0.26 (32) 4.37 ± 0.30 (35) < 0.0001
Resting membrane 
potential, mV (n)
-53.20 ± 1.23 
(12)
-52.76 ± 1.29 
(9)
0.8083
Cell capacitance, pF 
(n)
30.45 ± 1.25 
(12)
30.76 ± 1.86 
(11)
0.8884
Threshold for action 
potential, mV (n)
-43.27 ± 1.71 
(11)
-44.33 ± 2.49 
(9)
0.7225
Amplitude of action 
potential, mV (n)
62.82 ± 2.39 
(11)




94.12 (34) 97.22 (36) NA
Input resistance, MΩ 
(n)
386.6 ± 0.05 
(12)
295.4 ± 0.04 (8) 0.1840
Time constant, ms (n)
66.3 ± 11.45 
(12)
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Figure Legends 
Figure 1
Immunolocalization of oligomeric amyloid β (Aβ) within the LC of Alzheimer’s patients 
and APP-PSEN1 mice. (A1) in post-mortem samples from Alzheimer’s patients, 
immunoreactivity for an antibody that recognises both fibrillar and oligomeric forms of Aβ 
presents exclusively as extracellular plaques (arrowheads) with no intracellular signal 
evident in LC noradrenergic neurons, identified by immunoreactivity for tyrosine 
hydroxylase (TH) (asterisk). (A2-3) in APP-PSEN1 mice, immunoreactivity for Aβ is 
concentrated within LC noradrenergic neurons, with no evidence of extracellular plaques. 
(A4) is a magnified view of the boxed area in (A 2-3) demonstrating that Aβ is also 
expressed in non-noradrenergic LC neurons (arrowheads). n = 5 Alzheimer’s-control 
subjects, at least 5 APP-PSEN1-WT mice. (B) in LC samples from Alzheimer’s patients, 
immunoreactivity for an antibody specific for Aβ oligomers (AβO), termed AβO-NU2, 
shows enrichments within TH-immunopositive somata, together with extracellular 
clusters. n = 5 Alzheimer’s-control subjects. (C1-3) in LC samples from APP-PSEN1 
mice, an overview of immunoreactivity for AβO-NU2 reveals its enrichment throughout LC 
neurons, mirroring the expression pattern in Alzheimer’s samples. However, some TH-
immunopositive cells do not exhibit immunoreactivity for  AβO-NU2 (arrowheads). (C4) is 
a magnified view demonstrating that AβO-NU2 immunoreactivity is located within somata 
of LC neurons and profiles resembling axons (arrowheads). Individual extracellular 
clusters are also evident. n = > 5 APP-PSEN1 mice. (D) immunoreactivity for a different 
AβO antibody, termed NU1 that recognises oligomers different in size to NU2, in the LC 
of APP-PSEN1 mice. Note the significant variation in the intensity of the signal across 
different TH-immunopositive somata, with some cells (arrowheads) apparently devoid of 
any immunoreactivity. n = > 5 APP-PSEN1 mice. (E1-2) cytoplasmic AβO-NU1 signal is 
closely associated (arrowheads) with mitochondria, identified by immunoreactivity for the 
mitochondria matrix marker citrate synthase. A significant degree of overlap is evident in 
extracellular clusters which could represent axon terminals. n = > 5 APP-PSEN1 mice. 
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NU1 and citrate synthase, with Manders’ representing the degree of co-occurrence of 
overlapping pixels and Pearson’s the correlation of the intensity of overlapping pixels, n = 
50 cells. (F1-2) in the LC of APP-PSEN1 mice, cytoplasmic AβO-NU2 signal is also 
located in close proximity to citrate synthase. n = > 5 APP-PSEN1 mice. (F3) there is a 
positive association between the location of immunoreactivity for AβO-NU2 and citrate 
synthase, with Manders’ representing the degree of co-occurrence of overlapping pixels 
and Pearson’s the correlation of the intensity of overlapping pixels, n = 50 cells. (G) and 
(H), in the LC of APP-PSEN1 mice, cytoplasmic immunoreactivity for both AβO-NU1 and 
AβO-NU2 is closely associated with signal for superoxide dismutase 2 (SOD2), a key 
mitochondrial enzyme in oxidative stress. n = > 5 APP-PSEN1 mice. For both (G3) and 
(H3), n = 50 cells. (I 1-6) representative images of the relative levels of immunoreactivity 
for superoxide dismutase 2 (SOD2) in the LC of WT and APP-PSEN1 mice. Note the 
significant decrease in APP-PSEN1 samples of the intensity of signal for this enzyme 
which is protective against oxidative stress. (I7) quantification of SOD2 
immunofluorescence intensity in WT and APP-PSEN1 samples. Two-tailed unpaired 
Student’s t test, n = 5 animals. (J1-2) show immunoreactivity for IBA1, a marker of 
activated microglia, in the LC of WT and APP-PSEN1 respectively, reacted and imaged 
under identical conditions. There is an apparent increase in the density of profiles in the 
APP-PSEN1 image, suggestive of enhanced microglial activation. This increased IBA1 
expression in APP-PSEN1 samples was confirmed at the (J3) mRNA level (two-tailed 
unpaired Student’s t test, n = 5 animals) and (J4) cellular level (two-tailed unpaired 
Student’s t test, n = 10 animals). (J4-7) comparative LC and hippocampal mRNA 
expression levels of the cytokines colony stimulating factor 1 (CSF1), interleukin 1 β 
(IL1β) and chemokine (C-C motif) ligand 3 (CCL3) respectively. Two way (genotype and 
brain region) ANOVA with Sidak’s post hoc test, n = 5 animals. All immunohistochemical 
images presented represent a single optical section. The symbols represent the 
individual data points, the bars represent the means and the error bars the SEM. * = P < 
0.05. Scale bars: (A1) 30 µm; (A2-3) 50 µm; (A4) 15 µm; (B1-2) 15 µm; (C1-3) 100 µm; 
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Association of AβO with synapses and LC neuronal excitability in APP-PSEN1. (A) 
extracellular AβO-NU2 immunoreactivity is located in close apposition to clusters 
immunopositive for the pan-presynaptic marker protein, synaptic vesicle glycoprotein 2A 
(SV2A) (arrowheads), indicating expression at synaptic junctions. (A4) is a magnified 
view of the boxed areas in (A1-3). n = > 5 APP-PSEN1 mice. (B) extracellular AβO-NU2 
immunoreactive clusters are closely associated with inhibitory axon terminals, identified 
by immunoreactivity for the vesicular GABA transporter (VGAT) (arrowheads), indicating 
expression in close proximity to GABAergic synapses. (B4) is a magnified view of the 
boxed areas in (B1-3). n = > 5 APP-PSEN1 mice. (C) extracellular AβO-NU2 
immunoreactive clusters are closely associated excitatory axon terminals, identified by 
immunoreactivity for the vesicular glutamate transporter 2 (VGLUT2) (arrowheads), 
indicating expression in close proximity to glutamatergic synapses. (C4) is a magnified 
view of the boxed areas in (C1-3). n = > 5 APP-PSEN1 mice. (D1) representative image 
of a recorded neuron, loaded with biocytin during the recording, and processed post-hoc 
for TH immunohistochemistry, confirming that recorded neurons were located within the 
LC and were noradrenergic. 
(D2) representative traces of the spontaneous firing rates (FRs) of LC noradrenergic 
neurons in WT and APP-PSEN1 mice. Note the significantly higher FR in the trace for 
APP-PSEN1. (D3) quantification of the spontaneous FR (Hz) of LC noradrenergic 
neurons in WT and APP-PSEN1 mice. The data points represent individual cells. Two-
tailed unpaired Student’s t test, n = 32 cells for WT and 35 for APP-PSEN1.
(D4) quantification of the membrane time constant for WT and APP-PSEN1 mice. The 
data points represent individual cells. Two-tailed unpaired Student’s t test, n = 12 cells for 
WT and 9 for APP-PSEN1. (E) quantification of the concentration of noradrenaline in the 
LC and hippocampus of WT and APP-PSEN1 mice using an ELISA for NA. The data 
points represent individual mice. Two way (genotype and brain region) ANOVA, with 
Sidak’s post hoc test, n = 5 animals. (F1) concentration-dependent effect of the inhibitory 
role of GABA on spontaneous LC FR in WT mice, n = 4-7 cells per GABA concentration. 
(F2) diminished inhibitory effect of GABA in LC neurons form APP-PSEN1 mice. The 
data points represent individual cells. Two way (genotype and drug) ANOVA, n = 7 cells 
for WT and 13 for APP-PSEN1. (F3) percentage decrease in spontaneous LC FR 
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represent individual mice. Two-tailed unpaired Student’s t test, n = 7 cells for WT and 13 
for APP-PSEN1. (G1) demonstration that the majority of GABA release sites, identified by 
immunoreactivity for the vesicular GABA transporter (VGAT) are located adjacent to 
domains containing putative GABAA and glycine receptors, identified by immunoreactivity 
for the GABAA and glycine receptor anchoring protein gephyrin. (G2) in contrast to (G1), 
sparse clusters immunoreactive for the GABAB receptor are located on TH-
immunopositive profiles which rarely are located adjacent to VGAT-immunoreactive 
clusters. All immunohistochemical images presented represent a single optical section. 
The symbols represent the individual data points, the bars represent the means and the 
error bars the SEM. * = P < 0.05. 
Scale bars: (A1-3) 5 µm; (A4) 1 µm; (B1-3) 5 µm; (B4) 3 µm; (C) 2 µm; (D1) 10 µm; (D2) 
horizontal, 500 ms, vertical 20 mV; (G1) 10 µm; (G2) 5 µm.
Figure 3
Demonstration of native GABAA receptor (GABAAR) subtypes expressed in mouse and 
human LC neurons. (A1) TH immunoreactivity identifying noradrenergic neurons in the 
mouse LC. (A2) shows immunoreactivity for the GABAAR α1 subunit in the corresponding 
field of view. (A3) is a magnified overlay of the boxed areas in (A1 and A2) showing α1 
immunoreactivity is expressed in LC somata (asterisk) and dendrites of profiles which are 
TH-immunonegative. (A4) in the human LC, α1 immunoreactivity is also expressed 
exclusively in TH-immunonegative cells (asterisks). n = 5 human control subjects and > 5 
WT mice. (B) overview of LC α3 subunit immunoreactivity in WT and α3 gene deleted 
mice (α3 -/-), thereby confirming the specificity of the α3 antibody used, n = 4 WT and α3 -
/-animals. (C1-3) high resolution immunolocalization demonstrating that in the mouse LC, 
α3 immunoreactivity is concentrated on somatic and dendritic surfaces adjacent to GABA 
release sites (arrowheads), identified by immunoreactivity for VGAT. (C4), in the human 
LC, α3 immunoreactivity is also enriched on the somatic and dendritic (arrowheads) of 
noradrenergic neurons. n = 5 human control subjects and > 5 WT mice. Mouse LC 
noradrenergic neurons also express (D1) the γ2 and (D2) β3 subunits, which (D3) are 
closely associated with one another (arrowheads). (E1) α3 immunoreactivity is closely 
associated with immunoreactivity for (E2-3) the β3 subunit (arrowheads). (F) α3-
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the deletion of this subunit resulting in a significant increase (two-tailed unpaired 
Student’s t test, n = 32 WT cells, 16 α3-/- cells), whilst (E2) its pharmacological activation 
resulting in a significant decrease (two-tailed paired Student’s t test, n = 5 cells). All 
immunohistochemical images presented represent a single optical section. The symbols 
represent the individual data points, the bars represent the means and the error bars the 
SEM. * = P < 0.05. Scale bars: (A1-2) 30 µm; (A3) 10 µm; (A4) 20 µm; (B) 100 µm; (C) 15 
µm; (D) 10 µm; (E) 5 µm.
Figure 4
Interaction of AβO and α3-GABAARs in the LC of Alzheimer’s patients and APP-PSEN1 
mice. (A) representative image of the immunoreactivity pattern of the α3 subunit in the LC 
of a WT mouse. (B) representative image of the immunoreactivity pattern of the α3 
subunit in the LC of an APP-PSEN1 mouse, processed and imaged under conditions 
identical to WT samples. Note the sparse localisation of signal on somato-dendritic 
plasma membranes, with the majority of the signal preferentially located in cytoplasmic 
compartments. n = > 5 APP-PSEN1-WT mice. Quantification of the (C1) density, (C2) 
size, (C3) mean fluorescence intensity of α3 subunit immunoreactive clusters and (C4) 
percentage of cell area they occupy, in the LC of WT and APP-PSEN1 mice. Two-tailed 
unpaired Student’s t test, n = 40 cells for WT, and 50 for APP-PSEN1. (D) shows that in 
LC somata and dendrites of APP-PSEN1 mice, pools of AβO-NU2 immunopositive 
clusters overlap with clusters immunopositive the α3 subunit (arrowheads). (D4) is a 
magnified view of the boxed areas in (D1-3). (E) differences in the inhibitory effect of the 
α1/3/5-GABAAR positive allosteric modulator TP003 in LC neurons from WT and APP-
PSEN1 mice. While TP003 robustly inhibits LC FR in WT cells, there is no significant 
effect in cells from APP-PSEN1 mice. The data points represent individual cells. Two-way 
(genotype and drug) repeated measures ANOVA, n = 5 cells. (F1-3) representative 
image of immunoreactivity for the α3 subunit in the LC of control human tissue. (F4-6) 
representative image of immunoreactivity for the α3 subunit in the LC of an Alzheimer’s 
patient. Note how the α3 signal in patient material mirrors that of the APP-PSEN1 mouse, 
being predominantly restricted to cytoplasmic compartments, with significantly lower 
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(F7) quantification of the association between immunoreactivity for the α3 subunit and 
TH, as a measure of cytoplasmically located α3 subunit, using the Manders’ coefficient of 
the co-occurrence of overlapping pixels. The data points represent individual cells. P > 
0.05, Kolmogorov–Smirnov test, n = 110 cells per group. (G) representative image 
showing the lack of an association between signal for fibrillar Aβ (arrowheads) and the α3 
subunit in the LC of Alzheimer’s patients.  n = 5 Alzheimer’s subjects. (H) representative 
image showing that in the LC of Alzheimer’s patients, immunoreactivity for AβO-NU2 and 
the α3 subunit are located in close proximity to one another, in a pattern that mirrors 
expression in APP-PSEN1 mice. n = 5 Alzheimer’s subjects. All immunohistochemical 
images presented represent a single optical section. The symbols represent the 
individual data points, the bars represent the means and the error bars the SEM. * = P < 
0.05.  Scale bars: (A, B, D1-3) 10 µm; (D4) 5 µm; (F1-2; F4-5) 15 µm; (F3, F6) 6 µm; (G) 
15 µm; (H) 20 µm. 
Figure 5
Demonstration of native glycine receptor and transporter subtypes expressed in mouse 
LC neurons. (A) immunoreactivity for an antibody that recognises all GlyR α subunits and 
its close association with immunoreactivity for the vesicular GABA transporter (VGAT). n 
= > 5 WT mice. (B) concentration-dependent inhibitory effect of applied glycine on 
spontaneous LC FR. n = 10 cells. (C1-3) immunoreactivity for the glycine transporter 1 
(GlyT1) is associated with astrocytic profiles, identified by immunoreactivity for glial 
fibrillary acid protein (GFAP). n = > 5 WT mice. (C4) quantification of the frequency (Hz) 
of LC noradrenergic neuronal spontaneous firing before and after the bath application of 
1 μM ASP-2535, an inhibitor of GlyT1. Two-tailed paired Student’s t test, n = 8 cells. (D1-
3) immunoreactivity for the glycine transporter 2 (GlyT2) is associated with inhibitory axon 
terminals, identified by the immunoreactivity for VGAT. n = > 5 WT mice. (D4) 
quantification of the frequency (Hz) of LC noradrenergic spontaneous firing before and 
after the bath application of 1 μM ALX-1393, an inhibitor of GlyT2. Two-tailed paired 
Student’s t test, n = 8 cells. All immunohistochemical images presented represent a 
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represent the means and the error bars the SEM. * = P < 0.05. Scale bars: (A) 10 µm; (C, 
D) 20 µm.
Figure 6
Quantification of the changes in the expression and function of GlyRs and GlyTs in LC 
neurons of the APP-PSEN1 mice. (A1) and (A2) show representative images of the 
pattern and intensity of TH and GlyR immunoreactivity, respectively, in tissue from a WT 
mouse. (A3) and (A4) show the comparative TH and GlyR immunoreactivity patterns, 
respectively, in in tissue from an APP-PSEN1 mouse. Note that samples for (A1-2) and 
(A3-4) were reacted and imaged under identical conditions. Quantification of GlyR 
immunoreactive cluster (A5) density and (A6) area. (A7) quantification of the comparative 
inhibitory effects of applied glycine (30 nM) on spontaneous LC FR in WT and APP-
PSEN1 cells. (A5, 6) Two-tailed unpaired Student’s t test. (A7) Two way (genotype and 
drug) ANOVA with repeated measures, n = 10 WT cells and 9 APP-PSEN1 cells. (B1) 
and (B2) show representative images of the pattern and intensity of TH and GlyT2 
immunoreactivity, respectively, in tissue from a WT mouse. (B3) and (B4) show the 
comparative TH and GlyT2 immunoreactivity patterns, respectively, in in tissue from an 
APP-PSEN1 mouse. Note that samples for (B1-2) and (B3-4) were reacted and imaged 
under identical conditions. Quantification of GlyT2 immunoreactive cluster (B5) density 
and (B6) area. (B7) quantification of the comparative inhibitory effects of applied glycine 
transporter inhibitor ASP 1393 (1 µM) on spontaneous LC FR in WT and APP-PSEN1 
cells. (B5, 6) Two-tailed unpaired Student’s t test. (B7) Two way (genotype and drug) 
ANOVA with repeated measures, n = 10 WT cells, 5 APP-PSEN1 cells. All 
immunohistochemical images presented represent a single optical section. The symbols 
represent the individual data points, the bars represent the means and the error bars the 
SEM. * = P < 0.05. Scale bars: 20 µm. 
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